October 4, 2024
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the Remuneration Committee has decided to make amendments to the options issued to the Executive Directors at IPO in July 2021, and to those options issued to all current employees in 2021 or upon their appointment. Background and Rationale Under […]
• Read MoreOctober 2, 2024
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the acceptance for publication of data confirming analytical performance of the Company's blood-based LungLB® test in the journal BMC Pulmonary Medicine. Springer Nature's BMC Pulmonary Medicine is a globally recognised peer-reviewed medical journal with articles covering all aspects of the prevention, diagnosis and management of pulmonary and associated disorders. The […]
• Read MoreSeptember 4, 2024
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, is pleased to announce that our two abstract submissions to the Association for Molecular Pathology1 (AMP) have beenaccepted for both presentation at their flagship 2024 Annual Meeting & Expo in Vancouver, BC, Canada from November 19-23rd, and also for publication in the […]
• Read MoreAugust 22, 2024
LungLife AI, Inc. (the “Company” or “LungLife”) Half-year Report LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces its unaudited half-year report for the six months ended 30 June 2024. Strong progress with our LungLB® product Continued operational delivery : Financial Highlights: Commenting Paul Pagano, Chief Executive […]
• Read MoreAugust 16, 2024
LungLife AI, Inc. (the “Company” or “LungLife”) LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, is pleased to note the publication of the finalized Local Coverage Determination (LCD) titled “Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy” (L39654), issued by the Medicare Administrative Contractor (MAC) Noridian Healthcare […]
• Read MoreAugust 15, 2024
LungLife AI, Inc.(the “Company” or “LungLife”) Notice of Results Investor Briefing LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, will announce its unaudited half-year report for the six months ended 30 June 2024 on Thursday 22 August 2024. Investor presentation Paul Pagano, Chief Executive Officer, and […]
• Read MoreJune 5, 2024
LungLife AI, Inc. ("LungLife" or the "Company") Result of Annual General Meeting LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at its Annual General Meeting, held at earlier today, all 10 resolutions put to members were passed on a poll. Full details of the voting will be available […]
• Read MoreMay 15, 2024
LungLife AI, Inc. ("LungLife" or the "Company") Block Listing Six Monthly Return LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies: Name of applicant: LungLife AI, Inc. […]
• Read MoreApril 25, 2024
LungLife AI, Inc.(the “Company” or “LungLife”) Publication of Annual Report and Accounts & Notice of AGM LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the Annual Report and Accounts, Notice of Annual General Meeting ("AGM"), Form of Direction and associated Form of Proxy are now available on the Company’s […]
• Read More
LungLife AI licensure/accreditation information posted here.